Methodological aspects of lung cancer clinical trials in the era of targeted agents

Massimo Di Maio, Ciro Gallo, Ermelinda De Maio, Alessandro Morabito, Maria Carmela Piccirillo, Cesare Gridelli, Francesco Perrone

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Methodology of clinical trials conducted in lung cancer, similarly to other tumours, has been recently challenged by the particular characteristics of new targeted agents. Traditional methodology of phase II trials has been questioned, both for the choice of the endpoint and for the study design itself. Due to the mechanism of action of new drugs, cytostatic more than cytotoxic at least in principle, the usual endpoint of phase II trials, objective response rate, is now often replaced by alternative event-related endpoints, such as progression-free survival or progression-free rate at a fixed time-point. Randomized phase II trials, considered in the past the exception rather than the rule, have been encouraged, as the only design useful to give clear information on the activity of experimental treatments. Conduction of phase III trials remains mandatory to demonstrate treatment efficacy, but their endpoints and design are currently object of discussion. With targeted agents, great efforts have been made to identify predictive factors of treatment efficacy, but this aspect appears to be more complicated than hypothesized in principle. The history of clinical trials with epidermal growth factor receptor inhibitors in advanced NSCLC is a good example of the uncertainty about predictive factors and selection criteria. Moreover, non-inferiority design has been used for several phase III trials comparing targeted agents with chemotherapy. In this review, recent aspects of clinical trials methodology in lung cancer are described, and examples of their application are discussed.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalLung Cancer
Volume67
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Lung Neoplasms
Clinical Trials
Cytostatic Agents
Epidermal Growth Factor Receptor
Patient Selection
Disease-Free Survival
Uncertainty
History
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Bevacizumab
  • Cetuximab
  • Clinical trial methodology
  • Erlotinib
  • Gefitinib
  • Lung cancer
  • Sorafenib
  • Vandetanib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Methodological aspects of lung cancer clinical trials in the era of targeted agents. / Di Maio, Massimo; Gallo, Ciro; De Maio, Ermelinda; Morabito, Alessandro; Piccirillo, Maria Carmela; Gridelli, Cesare; Perrone, Francesco.

In: Lung Cancer, Vol. 67, No. 2, 02.2010, p. 127-135.

Research output: Contribution to journalArticle

Di Maio, Massimo ; Gallo, Ciro ; De Maio, Ermelinda ; Morabito, Alessandro ; Piccirillo, Maria Carmela ; Gridelli, Cesare ; Perrone, Francesco. / Methodological aspects of lung cancer clinical trials in the era of targeted agents. In: Lung Cancer. 2010 ; Vol. 67, No. 2. pp. 127-135.
@article{8699756a38744260807d7e243b16653c,
title = "Methodological aspects of lung cancer clinical trials in the era of targeted agents",
abstract = "Methodology of clinical trials conducted in lung cancer, similarly to other tumours, has been recently challenged by the particular characteristics of new targeted agents. Traditional methodology of phase II trials has been questioned, both for the choice of the endpoint and for the study design itself. Due to the mechanism of action of new drugs, cytostatic more than cytotoxic at least in principle, the usual endpoint of phase II trials, objective response rate, is now often replaced by alternative event-related endpoints, such as progression-free survival or progression-free rate at a fixed time-point. Randomized phase II trials, considered in the past the exception rather than the rule, have been encouraged, as the only design useful to give clear information on the activity of experimental treatments. Conduction of phase III trials remains mandatory to demonstrate treatment efficacy, but their endpoints and design are currently object of discussion. With targeted agents, great efforts have been made to identify predictive factors of treatment efficacy, but this aspect appears to be more complicated than hypothesized in principle. The history of clinical trials with epidermal growth factor receptor inhibitors in advanced NSCLC is a good example of the uncertainty about predictive factors and selection criteria. Moreover, non-inferiority design has been used for several phase III trials comparing targeted agents with chemotherapy. In this review, recent aspects of clinical trials methodology in lung cancer are described, and examples of their application are discussed.",
keywords = "Bevacizumab, Cetuximab, Clinical trial methodology, Erlotinib, Gefitinib, Lung cancer, Sorafenib, Vandetanib",
author = "{Di Maio}, Massimo and Ciro Gallo and {De Maio}, Ermelinda and Alessandro Morabito and Piccirillo, {Maria Carmela} and Cesare Gridelli and Francesco Perrone",
year = "2010",
month = "2",
doi = "10.1016/j.lungcan.2009.10.001",
language = "English",
volume = "67",
pages = "127--135",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Methodological aspects of lung cancer clinical trials in the era of targeted agents

AU - Di Maio, Massimo

AU - Gallo, Ciro

AU - De Maio, Ermelinda

AU - Morabito, Alessandro

AU - Piccirillo, Maria Carmela

AU - Gridelli, Cesare

AU - Perrone, Francesco

PY - 2010/2

Y1 - 2010/2

N2 - Methodology of clinical trials conducted in lung cancer, similarly to other tumours, has been recently challenged by the particular characteristics of new targeted agents. Traditional methodology of phase II trials has been questioned, both for the choice of the endpoint and for the study design itself. Due to the mechanism of action of new drugs, cytostatic more than cytotoxic at least in principle, the usual endpoint of phase II trials, objective response rate, is now often replaced by alternative event-related endpoints, such as progression-free survival or progression-free rate at a fixed time-point. Randomized phase II trials, considered in the past the exception rather than the rule, have been encouraged, as the only design useful to give clear information on the activity of experimental treatments. Conduction of phase III trials remains mandatory to demonstrate treatment efficacy, but their endpoints and design are currently object of discussion. With targeted agents, great efforts have been made to identify predictive factors of treatment efficacy, but this aspect appears to be more complicated than hypothesized in principle. The history of clinical trials with epidermal growth factor receptor inhibitors in advanced NSCLC is a good example of the uncertainty about predictive factors and selection criteria. Moreover, non-inferiority design has been used for several phase III trials comparing targeted agents with chemotherapy. In this review, recent aspects of clinical trials methodology in lung cancer are described, and examples of their application are discussed.

AB - Methodology of clinical trials conducted in lung cancer, similarly to other tumours, has been recently challenged by the particular characteristics of new targeted agents. Traditional methodology of phase II trials has been questioned, both for the choice of the endpoint and for the study design itself. Due to the mechanism of action of new drugs, cytostatic more than cytotoxic at least in principle, the usual endpoint of phase II trials, objective response rate, is now often replaced by alternative event-related endpoints, such as progression-free survival or progression-free rate at a fixed time-point. Randomized phase II trials, considered in the past the exception rather than the rule, have been encouraged, as the only design useful to give clear information on the activity of experimental treatments. Conduction of phase III trials remains mandatory to demonstrate treatment efficacy, but their endpoints and design are currently object of discussion. With targeted agents, great efforts have been made to identify predictive factors of treatment efficacy, but this aspect appears to be more complicated than hypothesized in principle. The history of clinical trials with epidermal growth factor receptor inhibitors in advanced NSCLC is a good example of the uncertainty about predictive factors and selection criteria. Moreover, non-inferiority design has been used for several phase III trials comparing targeted agents with chemotherapy. In this review, recent aspects of clinical trials methodology in lung cancer are described, and examples of their application are discussed.

KW - Bevacizumab

KW - Cetuximab

KW - Clinical trial methodology

KW - Erlotinib

KW - Gefitinib

KW - Lung cancer

KW - Sorafenib

KW - Vandetanib

UR - http://www.scopus.com/inward/record.url?scp=72449123164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449123164&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2009.10.001

DO - 10.1016/j.lungcan.2009.10.001

M3 - Article

VL - 67

SP - 127

EP - 135

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -